Psychedelic Stocks

Mydecine Innovations Inks Important Research Agreement

2020-06-30 TSI Editor

Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.

New Wave Holdings Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board

2020-06-30 TSI Reporter

New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.

Mydecine Innovations Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform

2020-06-30 TSI Reporter

Mydecine is acquiring the Digital Telehealth Platform of Mindleap Health Inc in a cash and shares deal.

Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD

2020-06-30 TSI Editor

Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.

Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board

2020-06-30 PSW Editor

Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.

Mydecine Innovations Group Adds a Leading Neuroscientist and a Psychopharmacology Specialist

2020-06-30 TSI Reporter

Mydecine's new Scientific Advisor will work directly with the CSO in new drug development initiatives.

Champignon Brands Announces Regulatory Review, Cease Trade Order

2020-06-30 TSI Reporter

Trading of Champignon Brands (SHRM) on the Canadian Securities Exchange has been temporarily halted due to the failure to file necessary disclosures with respect to recent acquisitions.